University of Vermont

The University of Vermont Cancer Center

Brain Cancer Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on brain cancer research.

Status: Active - Recruiting
Study Title: NRG BN001 - Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Purpose:The objective of this study, NRG BN001, is to determine if patients with newly diagnosed glioblastoma have improvement in overall survival if they are treated with higher doses of radiation delivered with temozolomide chemotherapy versus the current radiation dose and temozolomide chemotherapy.

The radiation for the protocol at UVM Medical Center will be delivered using standard external beam photon radiation via linear accelerator that we currently are using to treat all of our glioblastoma patients at UVM Medical Center. The dose for the Reference Arm (Arm A1) will be the standard of care dose of 60 Gray delivered over 30 treatments of 2 Gray per treatment. Arm A1 will treat the area of swelling around the tumor to 46 Gray in 23 treatments and then treat the tumor with an additional 14 Gray in 7 treatments.
The Experimental Arm (Arm B) will be the dose intensified photon radiation that will be delivered over 30 treatments. Arm B will treat the area of swelling around the tumor to 50 Gray in 30 treatments and simultaneously deliver an additional 25 Gray to the tumor throughout these 30 treatments.

All patients will be receiving standard dose of temozolomide chemotherapy which consists of a pill taken orally every day until the end of radiation and formulated at 75 mg/m2. After all radiation is completed, the patient will take temozolomide once daily for 5 days every 28 days and formulated at 150 mg/m2. This five day chemotherapy dosing will be delivered every 28 days for 6-12 months following the completion of radiation.

ClinicalTrials.gov Identifier: NCT0217906
Primary/Site/Co Investigator: Carl Nelson, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT02179086?term=Dose-Escalated+Photon+IMRT&rank=1
Institution Number: 15-262
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Purpose: This randomized phase III trial is studying different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor.
ClinicalTrials.gov Identifier: NCT00392327
Primary/Site/Co Investigator: Alan Homans, MD
Contact:Alan Homans (802) 847-2850
Information: http://clinicaltrials.gov/ct2/show/record/NCT00392327?term=COG+ACNS0332&rank=1
Institution Number: 00-327 COG ACNS0332
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: Imaging Lymphatic Drainage from Brain Tumors
Purpose: This is a non-randomized, open label study designed to track the pathways by which cancer from a specific type of brain tumor travels to “tumor-draining” lymph nodes in the neck. This is accomplished by surgically injecting a brain tumor with a radioactive tracer. The natural drainage of this tracer to the primary lymph node in the neck will be tracked using specialized medical imaging equipment that can display tracer movement. The two most significant impacts of a successful project outcome will be the establishment of lymphatic drainage from brain tumors, and the development of a readily-reproducible surgical technique to identify tumor-draining lymph nodes for clinical and scientific research. Our long-term objective is to develop an immunotherapy from these tumor-draining lymph nodes.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: David N. Krag, MD
Contact: Eileen Caffry (802) 656-3447
Information: N/A
Institution Number: M13-032
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
RTOG 1205 – Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Purpose: This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma.  It is not yet know whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma.
ClinicalTrials.gov Identifier: NCT01730950
Primary/Site/Co Investigator: Steve Emmons, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT01730950?term=RTOG+1205&rank=1
Institution Number: CHRMS M13-129
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas
Purpose: This is a Phase I non-randomized, open-label study in patients with newly diagnosed glioblastoma to determine the ability to generate human hybridomas from lymph nodes draining an autologous tumor vaccine injection and demonstrate that the hybridomas secrete glioblastoma-specific antibodies. The proposed approach would provide a personalized repertoire of antibodies that recognize unique glioblastoma-specific targetable antigens.
ClinicalTrials.gov Identifier: NCT01702792
Primary/Site/Co Investigator: David Krag, MD and Camilo Fadul, MD (Dr. Fadul is at Dartmouth Hitchcock Medical Center in NH)
Contact: Eileen Caffry (802) 656-3447
Information: http://clinicaltrials.gov/ct2/show/record/NCT01702792?term=hybridomas&rank=1
Institution Number: CHRMS M13-145
Protocol Research Type: Investigator Initiated
Status: Active - Closed to Accrual
Study Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The “ACT IV” Study). 
Purpose: This study is designed to find out whether adding treatment with the vaccine rindopepimut (also known as CDX-110) to the commonly used chemotherapy drug called Temozolomide helps to shrink brain tumors or prevents brain tumors from growing and helps patients with brain tumors live longer than treatment with Temozolomide alone.  Temozolomide is a standard treatment for Glioblastoma and all patients in this study will be administered Temozolomide according to routine practice. 
ClinicalTrials.gov Identifier: NCT01480479
Primary/Site/Co Investigator: Steven Emmons, MD
Contact: Kate Murray (802) 656-9401
Information: http://clinicaltrials.gov/ct2/show/NCT01480479?term=ACT+IV&rank=1
Institution Number: M12-100
Protocol Research Type: Industry Sponsored

Last modified June 04 2015 10:19 AM